| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8616010 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 22 Pages |
Abstract
Although the presence of severe comorbidities was lower when assessed by ACE-27 (13%) compared with HCT-CI (23%), and the spectrums of comorbidities captured were different, the overall impact of severe comorbidities as assessed by both scales appears to be similar and associated with a survival disadvantage.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Justyna Bartoszko, Tony Panzarella, Caroline Jane McNamara, Anthea Lau, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Dawn Maze, Karen W.L. Yee, Rebecca Devlin, Vikas Gupta,